Hot flushes and sweating, sleep problems, joint and muscular discomfort, and physical and mental exhaustion in breast cancer survivors during the first 24 months of tamoxifen therapy: a prospective observational study

Hot flushes and sweating, sleep problems, joint and muscular discomfort, and physical and mental exhaustion in breast cancer survivors during the first 24 months of tamoxifen therapy: a prospective observational study

PurposeThis study aimed to explore symptom trajectories over 24 months for hot flushes and sweating, sleep problems, joint and muscular discomfort, and physical and mental exhaustion experienced by premenopausal women diagnosed with tamoxifen-treated breast cancer.MethodsA total of 104 patients part...

Full description

Bibliographic Details
Main Authors:	Sumi Sung, Yul Ha Min, Seul Ki Park, Sae Byul Lee
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Oncology
Subjects:	adjuvant endocrine therapy breast cancer tamoxifen signs and symptoms premenopause
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.844926/full

Similar Items

A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study
by: Gu Ran, et al.
Published: (2012-05-01)

Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer
by: Montagna E, et al.
Published: (2021-09-01)

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project
by: Giacomo Pelizzari, et al.
Published: (2018-09-01)

Tamoxifen Effects on the lipid profile in premenopausal women with Breast cancer: A follow up study
by: Zainab A. M. Ali, et al.
Published: (2018-12-01)

Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
by: Christine Lundgren, et al.
Published: (2023-09-01)

A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis
by: Jin Hong, et al.
Published: (2020-07-01)

Association between tamoxifen and incidence of osteoporosis in Korean patients with ductal carcinoma in situ
by: Dooreh Kim, et al.
Published: (2024-01-01)

Longitudinal Trends in Illness Perception and Depression during Adjuvant Breast Cancer Endocrine Therapy: A Prospective Observational Study
by: Seul Ki Park, et al.
Published: (2021-09-01)

The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review
by: Leanne Fleming, et al.
Published: (2022-08-01)

The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis
by: Nicola Peddie, et al.
Published: (2021-08-01)

Severe hyperlipidemia pancreatitis induced by taking tamoxifen after breast cancer surgery—Case report
by: Chao Zhai, et al.
Published: (2023-03-01)

Is tamoxifen associated with an increased risk for thromboembolic complications in patients undergoing microvascular breast reconstruction? [Ist die Einnahme von Tamoxifen zum Zeitpunkt der mikrovaskulären Brustrekonstruktion mit einer erhöhten Rate an thrombembolischen Komplikationen assoziiert?]
by: Krämer, Robert, et al.
Published: (2013-02-01)

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer
by: Zhen-Yu Wu, et al.
Published: (2021-04-01)

Long-term efficacy of megestrol acetate and tamoxifen in a recurrent adult granulosa cell tumor of the ovary
by: Ashley S. Moon, et al.
Published: (2021-05-01)

Use of antipsychotics with tamoxifen
by: H. Ghabi, et al.
Published: (2021-04-01)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
by: Javier A. Menendez, et al.
Published: (2021-03-01)

Tamoxifen in the Management of Breast Cancer: A Case Presented in Multidisciplinary Session With Clinical Discussion and Decision-Making
by: Marziyeh Ghalamkari, et al.
Published: (2019-02-01)

Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea
by: Dooreh Kim, et al.
Published: (2023-02-01)

Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
by: Thomas Helland, et al.
Published: (2017-11-01)

Temporal influence of endocrine therapy with tamoxifen and chemotherapy on nutritional risk and obesity in breast cancer patients
by: Mariana Tavares Miranda Lima, et al.
Published: (2017-08-01)

Tamoxifen-induced hyperosmolar hyperglycemic state secondary to suspected pancreatic beta cell inflammation
by: Billie Radovic, et al.
Published: (2020-12-01)

Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ERα-Positive Breast Cancer
by: Vasiliki Vafeiadou, et al.
Published: (2022-02-01)

Fear of cancer recurrence in South Korean survivors of breast cancer who have received adjuvant endocrine therapy: a cross-sectional study
by: Seul Ki Park, et al.
Published: (2023-07-01)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
by: Butani D, et al.
Published: (2021-11-01)

Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years
by: Chiao-En Wu, et al.
Published: (2016-04-01)

EVALUASI TERAPI ADJUVAN DAN KEJADIAN RELAPS PADA PASIEN PREMENOPAUSAL EARLY BREAST CANCER DI RSUP DR. SARDJITO YOGYAKARTA
by: Fef Rukminingsih, et al.
Published: (2017-03-01)

Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients
by: Kirsten M. Woolpert, et al.
Published: (2024-04-01)

From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells
by: Jéssica Fernanda Barazetti, et al.
Published: (2021-07-01)

Repurposing the Selective Oestrogen Receptor Modulator Tamoxifen for the Treatment of Duchenne Muscular Dystrophy
by: Elinam Gayi, et al.
Published: (2018-04-01)

Repurposing of the Tamoxifen Metabolites to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli
by: Andrea Miró-Canturri, et al.
Published: (2021-03-01)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
by: Emily K. Zboril, et al.
Published: (2023-06-01)

Bilateral Macular Edema in a Patient Treated with Tamoxifen: A Case Report and Review of the Literature
by: Paraskevas Zafeiropoulos, et al.
Published: (2014-12-01)

Tamoxifen-induced acute pancreatitis – a case report
by: Rafał Czyżykowski, et al.
Published: (2014-03-01)

Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer
by: Javier A. Menendez, et al.
Published: (2020-10-01)

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
by: Roberta Rosso, et al.
Published: (2023-01-01)

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis
by: Hao Liao, et al.
Published: (2022-05-01)

Tamoxifen in horses: pharmacokinetics and safety study
by: Gonzalo Gajardo, et al.
Published: (2019-06-01)

The effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer
by: Seul Lee, et al.
Published: (2018-09-01)

Acquired Bilateral Nevoid Telangiectasia Induced by Tamoxifen
by: Irene Navarro Navarro, et al.
Published: (2023-04-01)

Effect of Tamoxifen on the Risk of Osteoporosis and Osteoporotic Fracture in Younger Breast Cancer Survivors: A Nationwide Study
by: Jihyoun Lee, et al.
Published: (2020-03-01)